AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12384804 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous TIL plus interleukin‐2 (IL‐2)
Number of subjects: 88
Study 12384804 — intervention group
Group type: COMPARATOR
Intervention: IL‐2 only
Number of subjects: 88
Study 10570677 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat diet
Number of subjects: 110
Study 10570677 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 110
Study 7624601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined astemizole, 20 mg, and ranitidine, 600 mg
Number of subjects: 14
Study 7624601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2655611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg/d
Number of subjects: 0
Study 2655611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg/d
Number of subjects: 0
Study 2655611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 200 mg/d
Number of subjects: 0
Study 2655611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg/d and 100 mg/d
Number of subjects: 0
Study 1252849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic Doppler angiography
Number of subjects: 40
Study 1252849 — intervention group
Group type: COMPARATOR
Intervention: Venography
Number of subjects: 40
Study 31025253 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help Cognitive Behavioral Therapy (CBT) workbook
Number of subjects: 140
Study 31025253 — intervention group
Group type: COMPARATOR
Intervention: Active psychoeducational control workbook
Number of subjects: 140
Study 30850240 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg‐AS01B
Number of subjects: 60
Study 30850240 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg‐Alum
Number of subjects: 60
Study 30850240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27395069 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy with transtympanic short-term tube insertion; tube in tympanic membrane for less than 12 months
Number of subjects: 156
Study 27395069 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy with transtympanic short-term tube insertion; incision in anterior-inferior quadrant
Number of subjects: 156
Study 27395069 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy with transtympanic short-term tube insertion; greater number of otitis episodes
Number of subjects: 156
Study 27395069 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy with transtympanic short-term tube insertion; greater number of otorrhea episodes
Number of subjects: 156
Study 27395069 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy with transtympanic short-term tube insertion; tympanogram type A after tube extraction
Number of subjects: 156
Study 25972136 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF; Daflon® 500 mg)
Number of subjects: 592
Study 25972136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study 23857160 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 51
Study 23857160 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal epidural anaesthesia
Number of subjects: 51
Study 22043671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture program with points in the neck, points in the glossopharyngeal part, and points selected according to syndrome differentiation, deep puncture, for 6 sessions
Number of subjects: 63
Study 22043671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture program with points in the neck, points in the glossopharyngeal part, and points selected according to syndrome differentiation, deep puncture, for 4 sessions
Number of subjects: 63
Study 22043671 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep puncture (C3)
Number of subjects: 63
Study 19481327 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave irradiation for 3 min (650W)
Number of subjects: 30
Study 19481327 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave irradiation for 2 min (650W)
Number of subjects: 30
Study 16566626 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (N=13)
Number of subjects: 35
Study 16566626 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (N=11)
Number of subjects: 35
Study 16566626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=11)
Number of subjects: 35
Study 12687289 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-14 (7.5 g/day)
Number of subjects: 41
Study 12687289 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 10980100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation (PCV)
Number of subjects: 18
Study 10980100 — intervention group
Group type: COMPARATOR
Intervention: Volume Control Ventilation (VCV)
Number of subjects: 18
Study 9378835 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse
Number of subjects: 32
Study 9378835 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan mouthrinse
Number of subjects: 32
Study 9378835 — intervention group
Group type: COMPARATOR
Intervention: Placebo control for essential oil mouthrinse
Number of subjects: 32
Study 9378835 — intervention group
Group type: COMPARATOR
Intervention: Placebo control for triclosan mouthrinse
Number of subjects: 32
Study 8335984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted reassortant influenza B/Yamagata/10/88 virus vaccine
Number of subjects: 14
Study 8335984 — intervention group
Group type: COMPARATOR
Intervention: Homologous B/Yamagata/88 wild-type virus
Number of subjects: 14
Study 3567042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (15 mg)
Number of subjects: 8
Study 3567042 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (15 mg)
Number of subjects: 8
Study 30341261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron with dexamethasone
Number of subjects: 30
Study 30341261 — intervention group
Group type: COMPARATOR
Intervention: Clonidine with dexamethasone
Number of subjects: 30
Study 27558788 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CBM (Cognitive Bias Modification)
Number of subjects: 78
Study 27558788 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (transcranial direct current stimulation)
Number of subjects: 78
Study 27558788 — intervention group
Group type: COMPARATOR
Intervention: Control CBM
Number of subjects: 78
Study 27558788 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS and CBM
Number of subjects: 78
Study 27558788 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 78
Study 27558788 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM and tDCS
Number of subjects: 78
Study 24431427 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory temporal tasks with simple and complex stimuli
Number of subjects: 0
Study 24431427 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual binding of audiovisual speech
Number of subjects: 0
Study 24431427 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 22008247 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily anticholinergic therapy plus a single intra‐detrusor injection of saline
Number of subjects: 242
Study 22008247 — intervention group
Group type: COMPARATOR
Intervention: Single intra‐detrusor injection of 100 U of botulinum toxin A plus daily oral placebo tablets
Number of subjects: 242
Study 21053477 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus bicarbonate powder (OBA: omeprazole 20 mg, sodium bicarbonate 1680 mg, alginic acid 250 mg)
Number of subjects: 48
Study 21053477 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole capsules (OMZ: omeprazole 20 mg)
Number of subjects: 48
Study 21053477 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole capsules (OMZ)
Number of subjects: 48
Study 21053477 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus bicarbonate powder (OBA)
Number of subjects: 48
Study 18672295 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 1052
Study 18672295 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1052
Study 15734783 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated recombinant coagulation factor VII (rFVIIa) 90 microg kg(‐1)
Number of subjects: 48
Study 15734783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15734783 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated recombinant coagulation factor VII (rFVIIa)
Number of subjects: 48
Study 12627298 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (6 weeks)
Number of subjects: 17
Study 12627298 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal training)
Number of subjects: 17
Study 10100180 — intervention group
Group type: EXPERIMENTAL
Intervention: Estroprogestin replacement therapy (ERT)
Number of subjects: 40
Study 8914118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin (CB12) 3 mg for 14 days
Number of subjects: 20
Study 8914118 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin (MB12) 3 mg for 14 days
Number of subjects: 20
Study 8914118 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-treatment observation for 9 days)
Number of subjects: 20
Study 1860150 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (E-Z) vaccine, 3.9 log 50 infectious units
Number of subjects: 124
Study 1860150 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz vaccine, 3.28 log 50 infectious units
Number of subjects: 124
Study 7173186 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg amoxicillin
Number of subjects: 10
Study 7173186 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg potassium clavulanate
Number of subjects: 10
Study 7173186 — intervention group
Group type: EXPERIMENTAL
Intervention: 625 mg amoxicillin and potassium clavulanate combination (augmentin)
Number of subjects: 10
Study 7173186 — intervention group
Group type: COMPARATOR
Intervention: Control (administration alone)
Number of subjects: 10
Study 31812956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target SBP 130-140 mm Hg) with standard-dose alteplase (0.9 mg/kg)
Number of subjects: 925
Study 31812956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target SBP 130-140 mm Hg) with low-dose alteplase (0.6 mg/kg)
Number of subjects: 925
Study 31812956 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure management (target SBP <180 mm Hg) with standard-dose alteplase (0.9 mg/kg)
Number of subjects: 925
Study 31812956 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure management (target SBP <180 mm Hg) with low-dose alteplase (0.6 mg/kg)
Number of subjects: 925
Study 30015580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration (DEH)
Number of subjects: 40
Study 30015580 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydration (EUH)
Number of subjects: 40
Study 30015580 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 40
Study 26445898 — intervention group
Group type: EXPERIMENTAL
Intervention: MPACT group (functional resistance and walking program)
Number of subjects: 20
Study 26445898 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 20
Study 26445898 — intervention group
Group type: EXPERIMENTAL
Intervention: MPACT group
Number of subjects: 20
Study 24439644 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology massage on the left foot for 20 minutes a day for 4 days
Number of subjects: 80
Study 24439644 — intervention group
Group type: COMPARATOR
Intervention: Gentle foot rub with oil for one minute
Number of subjects: 80
Study 21523893 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer-based sirolimus-eluting stent with six months of dual antiplatelet therapy (clopidogrel and aspirin)
Number of subjects: 2077
Study 21523893 — intervention group
Group type: COMPARATOR
Intervention: Prolonged clopidogrel therapy (>6 months)
Number of subjects: 2077
Study 19105915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment
Number of subjects: 498
Study 19105915 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 498
Study 17335116 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (3 g/day)
Number of subjects: 4
Study 17335116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 15489477 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular injections of triamcinolone acetate (20 mg, 40 mg/ml)
Number of subjects: 50
Study 15489477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study 11137804 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach
Number of subjects: 120
Study 11137804 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 120
Study 9775244 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 10
Study 7830631 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium cereal (50 g containing 12 g soluble fibre)
Number of subjects: 81
Study 7830631 — intervention group
Group type: COMPARATOR
Intervention: Wheat cereal (60 g containing 2 g soluble fibre)
Number of subjects: 81
Study 3139804 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed ovulation induction with clomiphene citrate and hMG
Number of subjects: 42
Study 3139804 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed ovulation induction with FSH and hMG
Number of subjects: 42
Study 3139804 — intervention group
Group type: COMPARATOR
Intervention: Nonprogrammed group (control)
Number of subjects: 42
Study 29654119 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute Integrity zotarolimus‐eluting stent
Number of subjects: 60
Study 29654119 — intervention group
Group type: COMPARATOR
Intervention: BioMatrix NeoFlex Biolimus A9‐eluting stent
Number of subjects: 60
Study 26453641 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-9054 morning dosing (1 drop to each eye at 07:00)
Number of subjects: 12
Study 26453641 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-9054 evening dosing (1 drop to each eye at 19:00)
Number of subjects: 12
Study 26453641 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) evening dosing
Number of subjects: 12
Study 25470888 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (group M, n=20)
Number of subjects: 60
Study 25470888 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (group L)
Number of subjects: 60
Study 25470888 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group C)
Number of subjects: 60
Study 22092389 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL of 2% lidocaine (low volume-high concentration)
Number of subjects: 120
Study 22092389 — intervention group
Group type: COMPARATOR
Intervention: 5 mL of 1% lidocaine (high volume-low concentration)
Number of subjects: 120
Study 20471807 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat-Githeri
Number of subjects: 554
Study 20471807 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-Githeri
Number of subjects: 554
Study 20471807 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-Githeri
Number of subjects: 554
Study 20471807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 554
Study 18950300 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetic patients
Number of subjects: 447
Study 18950300 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninsulin-treated diabetic patients
Number of subjects: 447
Study 18950300 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 447
Study 18950300 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (overall)
Number of subjects: 447
Study 16809351 — intervention group
Group type: EXPERIMENTAL
Intervention: BioBran MGN-3 (2 g three times per day for 8 weeks)
Number of subjects: 71
Study 16809351 — intervention group
Group type: COMPARATOR
Intervention: Placebo equivalent
Number of subjects: 71
Study 12809196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (n = 34)
Number of subjects: 93
Study 12809196 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (n = 30)
Number of subjects: 93
Study 12809196 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 29)
Number of subjects: 93
Study 11322158 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pass filtering with increasing cutoff
Number of subjects: 0
Study 11322158 — intervention group
Group type: COMPARATOR
Intervention: Inter-digit interval
Number of subjects: 0
Study 8880241 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous arteriovenous hemofiltration (CAVH)
Number of subjects: 27
Study 8880241 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hemodialysis (HD)
Number of subjects: 27
Study 1996592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine 30 mg/m2 over 30 minutes daily for 5 days every 4 weeks
Number of subjects: 17
Study 1996592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine 30 mg/m2 over 30 minutes daily for 5 days every 4 weeks with prednisone
Number of subjects: 17
Study 1996592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine therapy
Number of subjects: 17
Study 6093520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 91
Study 6093520 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 91
Study 31246609 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users (5,354 patients)
Number of subjects: 24528
Study 30381023 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 26653101 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH (Dietary Approaches to Stop Hypertension) intervention
Number of subjects: 90
Study 23836730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric feeding (30% calorie excess)
Number of subjects: 8
Study 23836730 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric feeding
Number of subjects: 8
Study 22160489 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆(9)‐tetrahydrocannabinol (THC)
Number of subjects: 0
Study 22160489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21148220 — intervention group
Group type: EXPERIMENTAL
Intervention: 20.9 lb (9.5 kg) carbon frame bicycle
Number of subjects: 1
Study 21148220 — intervention group
Group type: COMPARATOR
Intervention: 29.75 lb (13.5 kg) steel frame bicycle
Number of subjects: 1
Study 18055725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 64
Study 18055725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 16294079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine every 4 hours
Number of subjects: 44
Study 16294079 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) morphine
Number of subjects: 44
Study 11786571 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug induction regimen (standard or intensive timing)
Number of subjects: 90
Study 11786571 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 90
Study 11786571 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive nonmyeloablative chemotherapy
Number of subjects: 90
Study 11786571 — intervention group
Group type: COMPARATOR
Intervention: De novo AML
Number of subjects: 90
Study 11786571 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 90
Study 9820446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 412
Study 9820446 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 412
Study 7633746 — intervention group
Group type: EXPERIMENTAL
Intervention: Maneuver B: rapid exhalation from FRC to RV and long apnea at RV
Number of subjects: 9
Study 7633746 — intervention group
Group type: COMPARATOR
Intervention: Maneuver A: rapid exhalation from FRC to RV
Number of subjects: 9
Study 7633746 — intervention group
Group type: COMPARATOR
Intervention: Maneuver C: rapid exhalation from FRC to RV and short apnea at RV
Number of subjects: 9
Study 7633746 — intervention group
Group type: COMPARATOR
Intervention: Maneuver D: slow exhalation at a constant speed from FRC to RV
Number of subjects: 9
Study 7633746 — intervention group
Group type: COMPARATOR
Intervention: Maneuver E: curvilinear exhalation from FRC to RV
Number of subjects: 9
Study 2575981 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol 200mg daily
Number of subjects: 500
Study 2575981 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 100mg twice a day
Number of subjects: 500
Study 2575981 — intervention group
Group type: COMPARATOR
Intervention: nifedipine retard 20mg twice a day
Number of subjects: 500
Study 321088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0
Study 321088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29329046 — intervention group
Group type: EXPERIMENTAL
Intervention: Social contact intervention
Number of subjects: 219
Study 29329046 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 219
Study 27398897 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-guided minimally invasive spine surgery (RO)
Number of subjects: 30
Study 27398897 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic-guided open surgery (FA)
Number of subjects: 30
Study 25689244 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 15
Study 25689244 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg/day
Number of subjects: 15
Study 25689244 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading dose, then 75 mg/day)
Number of subjects: 15
Study 25689244 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine with Clopidogrel
Number of subjects: 15
Study 25689244 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram with Clopidogrel
Number of subjects: 15